Alzamend Neuro Inc. recently issued 243,429 shares of common stock upon the conversion of approximately 564.76 shares of Series B Convertible Preferred Stock. These transactions occurred between July 23 and July 30, 2025, under an exemption from registration requirements as per Section 4(a)(2) of the Securities Act. As of July 30, 2025, the company had a total of 3,139,861 shares of common stock outstanding. The document does not disclose the other party involved in the transaction or the price of the shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.